This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new indications and recent first-time generic launches.

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new indications and recent first-time generic launches.

Annual conference gathers 2,500+ managed care leaders to discuss complex health care issues.

Read Drug Approvals Monthly Update: January 2024 Critical updates in an ever-changing environment. Drug Approval Update Specialty New drugs 12/22/2023 Wainua™ (eplontersen) The United States (U.S.)...

Read Drug Approvals Monthly Update: February 2024 This monthly approval update provides a review of newly approved specialty drugs, recent drug launches, generic updates, new indications and news...

publications Spring 2024 Prime Therapeutics Report March 15, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 6)...

13th annual report the preeminent source for medical benefit drug trend

Managed Healthcare Executive

publications High-Cost Therapy Profile: March 2025 Pegzilarginase Intravenous (IV), Subcutaneous (SC) | Immedica Metabolic March 14, 2025 Proposed indications Arginase 1 deficiency (ARG1-D)...

Breadcrumb Home Newsroom Custom Content Publications Drug Approvals Monthly Update: September 2024 PUBLICATIONS Drug Approvals Monthly Update: September 2024 This monthly update of United States...

Get the most value and best outcomes from C&GT Cell and gene therapies (C&GTs) represent breakthrough science, but often come at a high cost. Breadcrumb Home Our solutions Condition management Cell...

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Read Drug Approvals Monthly Update: June 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Perspectives High-Cost Therapy Profile: April Detailed information about prademagene zamikeracel Topical surgical application Date High Cost Therapy Profile Gene therapy/Dermatology Prademagene...

PUBLICATIONS FDA Decisions Expected Drug pipeline for January 2025 December 17, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned...

Read Drug Approvals Monthly Update: April 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Breadcrumb Home Read, watch, listen Read Explore what's trending at Prime Example Link Example Link Card Title example Example Link Example Link Card Title example The Latest Tab 1 Press Releases...

Perspectives High-Cost Therapy Profile: May Detailed information about Fidanacogene elaparvovec-dzkt Intravenous (IV) High Cost Therapy Profile Gene therapy/Hematology Fidanacogene elaparvovec-dzkt...

Drug Approvals Quarterly Update: July 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process....

PUBLICATIONS FDA Decisions Expected: March 2025 Your monthly synopsis of new drugs expected to hit the market February 14, 2025 Drug pipeline for March 2025 At Prime Therapeutics (Prime), we have...

publications FDA Decisions Expected Drug pipeline for November 2024 October 14, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have...

Read Drug Approvals Monthly Update: May 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

publications High Cost Therapy Profile: November 2024 Zenocutuzumab Intravenous (IV) November 20, 2024 Oncology Proposed indications Pancreatic ductal adenocarcinoma (PDAC) and non–small...

Managed Healthcare Executive

USA Today

Reuters

Insider

CNBC

Formulary Watch

Star Tribune

Business Insider

Endpoint News

Reuters

Reuters

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

Reuters

Reuters

NBC News: Patients weren't asked why they quit taking the weight loss drugs

PUBLICATIONS FDA Decisions Expected: June 2025 Your monthly synopsis of new drugs expected to hit the market May 21, 2025 Drug pipeline for June 2025 At Prime Therapeutics (Prime), we have...

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs